Corebridge Financial’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Corebridge Financial’s Portfolio PSTX Stock Details PSTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-34,132	Closed	-$328K	–	3041
2024 Q4	$328K	Sell	34,132 -2,576	-7%	-$13.4K	﹤0.01%	1896
2024 Q3	$105K	Sell	36,708 -227	-0.6%	-$703	﹤0.01%	2597
2024 Q2	$108K	Buy	+36,935	New	+$101K	﹤0.01%	2558

Other funds holding PSTX

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Corebridge Financial's PSTX Position: Q1 2025 in Review

Corebridge Financial sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q1 2025, closing a stake of 34,132 shares — an estimated $328K sold.

Corebridge Financial first reported a position in PSTX in Q2 2024 and held it in 3 quarters. The position peaked at $328K in Q4 2024. 1 fund tracked by Wall St. Rank holds PSTX as of Q1 2025.

Corebridge Financial reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
Corebridge Financial sold 34,132 Poseida Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $328K.
Corebridge Financial first reported a position in Poseida Therapeutics, Inc. Common Stock in Q2 2024 and held it in 3 quarters.
Corebridge Financial's Poseida Therapeutics, Inc. Common Stock position peaked at $328K in Q4 2024.
1 fund tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q1 2025.

Based on Corebridge Financial's 13F filing for Q1 2025, filed 14 May 2025.